GlobeNewswire

Global Pneumonia Testing Industry

ReportLinker
23 min read

Global Pneumonia Testing Market to Reach $2 Billion by 2027. Amid the COVID-19 crisis, the global market for Pneumonia Testing estimated at US$1. 2 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 7.

New York, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pneumonia Testing Industry" - https://www.reportlinker.com/p05896281/?utm_source=GNW
9% over the analysis period 2020-2027. Immunodiagnostics, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$382.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Molecular Diagnostics segment is readjusted to a revised 6.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $317.9 Million, While China is Forecast to Grow at 11.8% CAGR

The Pneumonia Testing market in the U.S. is estimated at US$317.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$445 Million by the year 2027 trailing a CAGR of 11.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Point of Care Testing Segment to Record 9.1% CAGR

In the global Point of Care Testing segment, USA, Canada, Japan, China and Europe will drive the 8.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$382.8 Million in the year 2020 will reach a projected size of US$675.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$278.2 Million by the year 2027, while Latin America will expand at a 10.6% CAGR through the analysis period. We bring years of research experience to this 7th edition of our report. The 287-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Abbott Laboratories

  • AdvanDx, Inc.

  • Beckman Coulter, Inc.

  • Becton, Dickinson and Company

  • bioMerieux SA

  • Bio-Rad Laboratories, Inc.

  • Cepheid, Inc.

  • concile GmbH

  • Diamedix Corporation

  • DiaSorin SpA

  • F. Hoffmann-La Roche AG

  • Fast Track Diagnostics Luxembourg S.a.r.l.

  • Hologic, Inc.

  • Meridian Bioscience, Inc.

  • Quest Diagnostics, Inc.

  • Quidel Corporation

  • Seracare Life Sciences, Inc.

  • Thermo Fisher Scientific, Inc.

  • Trinity Biotech PLC

and

Recommended Stories